NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
Clinical Trials
26 trialsNCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05907122 2026-03-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT02224781 2026-02-18
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06054555 2026-01-12
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen
Phase 3 Active not recruiting
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT05625399 2025-08-24
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06640530 2025-07-08
UNIVERSE
Biocad
Phase 3 Active not recruiting
NCT01844505 2025-05-21
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb
Phase 3 Completed
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT03635983 2025-04-01
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT05297565 2025-02-27
CheckMate-6GE
Bristol-Myers Squibb
Phase 3 Completed
NCT06519266 2024-11-25
SCANDIUM-III
Vastra Gotaland Region
Phase 3 Recruiting
NCT04309409 2024-05-23
NivoMela
University Hospital, Essen
Phase 3 Active not recruiting
NCT04949113 2024-03-08
NADINA
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT01721772 2022-07-12
CheckMate 066
Bristol-Myers Squibb
Phase 3 Completed
NCT02714218 2022-06-24
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01721746 2022-04-19
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb
Phase 3 Completed
NCT03068455 2021-09-20
CheckMate 915
Bristol-Myers Squibb
Phase 3 Completed
NCT03329846 2021-07-09
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT02599402 2021-06-15
CheckMate 401
Bristol-Myers Squibb
Phase 3 Completed
NCT02905266 2020-12-17
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
Bristol-Myers Squibb
Phase 3 Completed